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Introduction: Despite the importance of dopamine neurotransmission in schizophrenia,
very few studies have addressed anomalies in the mesencephalic dopaminergic neurons
of the substantia nigra/ventral tegmental area (SN/VTA). Tyrosine hydroxylase (TH) is the
rate-limiting enzyme for the production of dopamine, and a possible contributor to the
anomalies in the dopaminergic neurotransmission observed in schizophrenia. Objectives:
In this study, we had three objectives: (1) Compare TH expression (mRNA and protein) in
the SN/VTA of schizophrenia and control postmortem samples. (2) Assess the effect of
antipsychotic medications on the expression of TH in the SN/VTA. (3) Examine possible
regional differences in TH expression anomalies within the SN/VTA. Methods:To achieve
these objectives three independent studies were conducted: (1) A pilot study to compare
TH mRNA andTH protein levels in the SN/VTA of postmortem samples from schizophrenia
and controls. (2) A chronic treatment study was performed in rodents to assess the effect
of antipsychotic medications inTH protein levels in the SN/VTA. (3) A second postmortem
study was performed to assess TH and phosphorylated TH protein levels in two types of
samples: schizophrenia and control samples containing the entire rostro-caudal extent of
the SN/VTA, and schizophrenia and control samples containing only mid-caudal regions of
the SN/VTA. Results and Conclusion: Our studies showed impairment in the dopamin-
ergic system in schizophrenia that could be mainly (or exclusively) located in the rostral
region of the SN/VTA. Our studies also showed that TH protein levels were signiﬁcantly
abnormal in schizophrenia, while mRNA expression levels were not affected, indicating
that TH pathology in this region may occur posttranscriptionally. Lastly, our antipsychotic
animal treatment study showed that TH protein levels were not signiﬁcantly affected by
antipsychotic treatment, indicating that these anomalies are an intrinsic pathology rather
than a treatment effect.
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INTRODUCTION
Tyrosine hydroxylase (TH) is a crucial enzyme in the produc-
tion of dopamine and other catecholamines. In the substantia
nigra/ventral tegmental area (SN/VTA), dopamine is the ﬁnal
product of cells that express TH, and these cells are the largest
source of dopamine in the brain. Studies of TH in the SN/VTA of
schizophrenia subjects are almost anecdotal, with just one study
that addressed enzymatic activity (Toru et al., 1988), and two stud-
ies that addressed mRNA levels (Ichinose et al., 1994; Mueller
et al., 2004). However, no studies have assessed TH protein lev-
els in the SN/VTA in schizophrenia. In addition, recent studies
on the synthesis of TH have shown that the regulation of the
production of TH is very different in the SN/VTA than in other cat-
echolaminergic neurons (Wong and Tank, 2007; Chen et al., 2008;
Tank et al., 2008). These studies also showed that posttranscrip-
tional regulations have a crucial role in the synthesis of TH in the
SN/VTA (Chen et al., 2008; Tank et al., 2008). Posttranscriptional
modulation occurs after the production of mRNA is completed,
and includes the stabilization of the mRNA, the attachment to
polyribosomes, and the regulation of the efﬁcacy of translation
into protein (Tank et al., 2008; Lenartowski and Goc, 2011). For
all these reasons, we believe that is necessary to study TH protein
levels in the SN/VTA in schizophrenia, to assess the possibility of
pathologies that could be located in posttranscriptional steps in
the synthesis of TH, rather than at the transcription level.
In addition to its production,THprotein activity in the SN/VTA
is modulated by the phosphorylation of certain serine sites in
the ﬁrst 40 amino acids of the N-terminus of the TH protein
(Haycock, 1990; Nakashima et al., 2009). Of these phosphoryla-
tion sites, serine 40 has been shown to be the most important
in the regulation of TH activity in the brain (Nakashima et al.,
2009). The phosphorylation of this site is a complex process that
requires proper conservation of the amino acid residues ﬂank-
ing this serine residue, and phosphorylation of this site produces
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the disinhibition of the catalytic subunit of TH, thus allowing the
production of dopamine (Nakashima et al., 2009).
Genetic association studies in schizophrenia have produced
somewhat inconclusive results (Meloni et al., 1995;Wei et al., 1995;
Jonsson et al., 1996, 1998; Thibaut et al., 1997; Burgert et al., 1998;
Ishiguro et al., 1998; Kunugi et al., 1998; Kurumaji et al., 2001; Ota
et al., 2001; Chao and Richardson, 2002; Pae et al., 2003; Hoogen-
doorn et al., 2005; Jacewicz et al., 2008; Talkowski et al., 2008;
Andreou et al., 2009). However, some of these studies have shown
consistent data in different cohorts of patients, indicating an asso-
ciation of certain mutations in the ﬁrst intron of the TH gene
with a higher risk of schizophrenia (Meloni et al., 1995; Wei et al.,
1995; Kurumaji et al., 2001; Pae et al., 2003; Jacewicz et al., 2008).
Interestingly this ﬁrst intron of the TH gene has been postulated
to be a modulatory region for the synthesis of TH (Pae et al., 2003;
Jacewicz et al., 2008).
Previous studies assessing anomalies of the dopaminergic sys-
tem in schizophrenia have heavily focused their attentionondiffer-
ent aspects of the dopamine neurotransmission at the postsynaptic
level, and studies of molecules involved in the transport and degra-
dation of dopamine (see as reviews, Abi-Dargham et al., 2010;
Perez-Costas et al., 2010; Tost et al., 2010). Another important
aspect of the dopaminergic neurotransmission, which originates
in neurons in the SN/VTA, is the topographical organization of
the dopamine-producing cells in this complex, which deﬁnes the
preferential terminal target of their projections (e.g., themesolim-
bic, mesocortical, or nigro-striatal pathways; Fallon and Moore,
1978a,b; Fallon et al., 1978a,b; Porrino and Goldman-Rakic, 1982;
Gaspar et al., 1992; McRitchie et al., 1995; Haber and Fudge, 1997;
Haber and Gdowski, 2004; Halliday, 2004). Some studies have
found anomalies in TH in the terminals of the nigro-striatal path-
way in schizophrenia (Roberts et al., 2009) and in the terminal
ﬁelds of the mesocortical pathway (Akil et al., 1999, 2000), but
none of theses studies have assessed the cells of origin of the
dopaminergic inputs to these brain regions. This brought our
attention to the importance of assessing regional anomalies in
TH synthesis within the SN/VTA in schizophrenia.
MATERIALS AND METHODS
ETHICS STATEMENT
All the human brain samples used in this studywere obtained from
the Maryland Brain Collection (Maryland Psychiatric Research
Center, University of Maryland School of Medicine) with permis-
sion from the Maryland Brain Collection Steering Committee. All
experimental procedures were also approved by the University of
Alabama at Birmingham Institutional Review Board (protocol #
N110505002) and in accordance with The Code of Ethics of the
World Medical Association.
All the animal experiments were conducted at the University of
Maryland following a protocol approved by the Institutional Ani-
mal Care and Use Committee (protocol # 0705010), in accordance
with National Institutes of Health guidelines regarding the care
and use of animals for experimental procedures.
POSTMORTEM HUMAN BRAIN SAMPLES
For all the postmortem human cases used in this study, two inde-
pendent senior psychiatrists established DSM-IV diagnoses based
on the review of all availablemedical records and the data obtained
from the Structured Clinical Interview for DSM-IIIR (Spitzer
et al., 1992) and DSM-IV Axis I disorders with the next of kin.
Control cases had enough information from next of kin andmed-
ical records to discard any major neurological or neuropsychiatric
disorders.
Two types of samples were used in this study: samples con-
taining the entire rostro-caudal extent of the SN/VTA (pilot study
and second postmortem study), and samples containing onlymid-
caudal SN/VTA (second postmortem study). In both cases samples
were frozen on dry ice and stored at−80˚C until use. Samples were
sectioned on a cryostat at −20˚C obtaining ﬁve parallel series of
16μm thick sections. Four parallel series were collected on super-
frost slides, while the ﬁfth series was collected in a tube for protein
extraction. In all cases, series #1 was stained with thionin (Nissl
stain) to assess possible morphological anomalies. Only cases that
presented good preservation of the SN/VTA region were included
in the study. The parameters used in this ﬁrst inspection under
the microscope included discarding any tissue sample that pre-
sented extensive autolysis of cells, cell shrinkage, and general bad
morphological preservation. In addition, all the cases that were
preselected after thismicroscopic assessment were also checked for
abnormally low actin levels (as an indicator of poor protein preser-
vation). Rostral and caudal limits for the SN/VTAwere determined
using the Paxinos and Huang (1995) brainstem atlas. For samples
containing only mid-caudal regions the rostral limit was set at
the starting point of the substantia nigra compacta (SNc) pars
ventralis as deﬁned by McRitchie et al. (1995).
Two different sets of experiments were performed with human
brain samples: (a) a pilot study in which TH mRNA and TH
protein levels were assessed in samples from the same cases (see
Table 1); (b) a second postmortem study of total TH protein lev-
els and phosphorylated TH (pTH) levels in samples containing
the entire extent or only mid-caudal regions of the SN/VTA (see
Table 2). In both tables information on antipsychotic medica-
tion taken at time of death is provided. However, it is likely that
during the duration of illnessmost of the schizophrenia cases were
exposed tomultiple antipsychotic therapies. In addition, inTable 2
there are two schizophrenia cases labeled as“unknownmedication
at time of death.” This refers to the fact that at time of death, it
was not known if they were actively taking any antipsychotic med-
ication, although they did not meet the criteria to be classiﬁed as
“off-drugs” (i.e., more than 3 or 6months reportedly not taking
antipsychotics).
ANIMAL SAMPLES
A total of 27 adult male Sprague-Dawley rats (Charles River Labo-
ratories,Wilmington,MA,USA) were used in this study to test the
effect of chronic treatment with antipsychotic drugs on TH pro-
tein levels. Animals were allowed to adapt to the animal room for
1week prior to starting any treatment, andwater consumptionwas
monitored to calculate initial treatment doses. Animals were then
randomly assigned to one of the three treatment groups (n = 9 per
group): haloperidol (1.5mg/kg/day),olanzapine (6mg/kg/day),or
control. Antipsychotics were administered for 3weeks in drink-
ing water, adjusting the doses to body weight and daily liquid
consumption as previously described in Perez-Costas et al. (2008).
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Table 1 | Pilot study: demographic table and clinical data in schizophrenia and controls.
Case # Age (years) Race gender COD PMI (hours) pH SZ subtype APD type TD
SCHIZOPHRENIA (N=6)
SZ1 53 C M ASCVD 14 6.01 Undifferentiated Quetiapine (A) Yes
SZ2 48 AA M Narcotic intoxication 24 7.07 NOS Quetiapine (A) un
SZ3 83 C M Electrocution 18 6.98 NOS Quetiapine (A) un
SZ4 46 C F DVT 25 6.18 NOS Clozapine (A) un
SZ5 54 C M Suicide (bleeding) 19 6.58 NOS Quetiapine (A) No
SZ6 42 AA F ASCVD/MI 13 5.86 Chronic paranoid Fluphenazine and Quetiapine (T+A) Yes
Mean 54.33 18.80 6.45
SD 14.73 4.96 0.51
CONTROLS (N=5)
C1 49 AA F Asthma 19 6.19
C2 51 AA M ASCVD 19 7.18
C3 45 C F Cardiac arrhythmia 16 6.69
C4 62 C M Cardiac arrest 19 6.48
C5 67 AA M ASCVD 17 6.68
Mean 54.80 18.0 6.64
SD 9.28 1.41 0.36
A, atypical antipsychotic; AA, African American; APD, antipsychotic drug; ASCVD, arteriosclerotic cardiovascular disease; C, Caucasian; COD, cause of death; DVT,
deep vein thrombosis; F, female; M, male; MI, myocardial infarction; NOS, not otherwise speciﬁed; PMI, postmortem interval; SD, standard deviation; SZ subtype,
schizophrenia subtype; T, typical antipsychotic; TD, tardive dyskinesia; un, unknown.
At endpoint, animals were decapitated and trunk blood was col-
lected to monitor plasma drug levels. Brains were immediately
removed from the skull, frozen in dry ice, and stored at −80˚C
until use. Four parallel series at the level of the SN/VTA were
collected on superfrost slides, while the ﬁfth series was collected
in a tube for protein extraction. For all animals, series #1 was
stained with thionin to assess possible morphological anom-
alies. No morphological anomalies were found in any of the
samples used.
IN SITU HYBRIDIZATION
In situ hybridization was performed for the postmortem SN/VTA
samples included in the pilot study (Table 1). Slides containing
sections at the level of the rostral, medial, and caudal SN/VTA
were selected from each case to perform this technique. To select
the sections, series #1 (stainedwith thionin) was used to accurately
identify matching rostral, medial, and caudal areas of the SN/VTA
for each case. A 48-mer antisense oligonucleotide probe that
hybridizes to nucleotides 32–79 of the humanTHmRNA sequence
was used. This sequence is common to all three mRNA transcript
variants identiﬁed for the human TH (GenBank accession num-
bers: NM_199292; NM_000360; NM_199293). Probe labeling,
hybridization, and post-hybridization rinses, were performed as
described in Gao et al. (1998). Brieﬂy, oligonucleotide probes were
labeled with 35S-dATP at the 3′-end using terminal transferase.
The sections were hybridized overnight at 37˚C with an hybridiza-
tion buffer containing 50% deionized formamide, 4× sodium
saline citrate (SSC),Denhardt’s solution,10×dextran sulfate, yeast
tRNA (250μg/ml), single strand salmon DNA (500μg/ml), and
100mM dithiothreitol (DTT). After hybridization, the sections
were sequentially rinsed in 1× SSC containing 10mM DTT at
55˚C, and 1× SSC at room temperature. Finally, the sections
were gradually dehydrated in ethanol, air dried, and autoradi-
ograms were generated by exposing Kodak BioMax MR ﬁlms
(Kodak, Rochester, NY, USA) along with [14C] microscale stan-
dards (Amersham Biosciences, Little Chalfont, UK) for 14 days.
Films were developed using Kodak D-19 developer and ﬁxer,
scanned at 600 dpi, and optical density was measured using Image
Pro-Plus 6.2 software (Media Cybernetics, Bethesda, MD, USA).
For each case, two sections from each rostro-caudal region of the
SN/VTA (rostral, mid, caudal), were randomly selected for analy-
sis (i.e., six sections total were analyzed per case for the entire
rostro-caudal SN/VTA).
WESTERN-BLOT
Western-blot assays were performed for human postmortem
SN/VTA protein samples (pilot study and second postmortem
study; see Tables 1 and 2), and for rat SN/VTA protein samples
(animal study). In all cases the protein extraction procedure and
sample handling were identical. One entire series of the SN/VTA
from each case was collected on a tube. This series contained
sections (80μmapart each) from the entire mid-caudal regions of
the SN/VTA (mid-caudal cases for the second postmortem study),
or from the entire rostro-caudal extent of the SN/VTA (all the
other samples). The only differences were the antibodies used
for the detection of TH. For the human postmortem studies a
mouse monoclonal anti-TH antibody (Sigma-Aldrich, St. Louis,
MO, USA) diluted 1:10,000 was used, while for the animal study
a mouse monoclonal anti-TH antibody (Millipore, Billerica, MA,
USA) diluted 1:20,000 was used. In addition, a rabbit polyclonal
anti-phospho-Ser40 TH antibody (PhosphoSolutions,Aurora,CO,
USA) diluted 1:4,000 was used in human samples (second post-
mortem study) for the detection of pTH. Finally, reblots for actin
were performed in all the western-blot experiments (human and
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Table 2 | Demographic table and clinical data second postmortem study.
Case # Age (years) Race Gender COD PMI
(hours)
pH SZ subtype APD type TD
SCHIZOPHRENIA: ROSTRO-CAUDAL SAMPLES (N=8)
SZ1 53 C M ASCVD 14 6.01 Undifferentiated Quetiapine (A) Yes
SZ2 48 AA M Narcotic intoxication 24 7.07 NOS Quetiapine (A) un
SZ3 83 C M Electrocution 18 6.98 NOS Quetiapine (A) un
SZ4 46 C F DVT 25 6.18 NOS Clozapine (A) un
SZ5 54 C M Suicide (bleeding) 19 6.58 NOS Quetiapine (A) No
SZ6 42 AA F ASCVD/MI 13 5.86 Chronic paranoid Fluphenazine and Quetiapine (T+A) Yes
SZ7 25 C M Suicide (hanging) 20 5.90 Chronic paranoid Risperidone (A) Yes
SZ8 77 C M ASCVD 17 6.84 CUT Risperidone (A) un
Mean 53.50 18.75 6.43
SD 18.70 4.27 0.50
SCHIZOPHRENIA MID-CAUDAL SAMPLES (N=8)
SZ9 42 AA M Suicide (stabbing) 10 7.10 Chronic paranoid Haloperidol (T) Yes
SZ10 69 AA M ASCVD 14 6.71 CUT Haloperidol (T) No
SZ11 48 C F Respiratory arrest 21 7.80 CUT Clozapine (A) No
SZ12 42 AA M Pulmonary embolism 16 7.10 Chronic paranoid Haloperidol and Chlorpromazine (T) Yes
SZ13 77 AA F ASCVD 17 6.20 NOS UNK un
SZ14 67 AA M ASCVD 7 7.17 CUT UNK un
SZ15 47 AA M ASCVD 20 6.95 Chronic paranoid Fluphenazine (T) No
SZ16 37 C M Suicide (electrocution) 14 6.68 Chronic paranoid Risperidone and Fluphenazine (T+A) No
Mean 53.60 14.90 6.96
SD 15.00 4.73 0.46
CONTROLS: ROSTRO-CAUDAL SAMPLES (N=6)
C2 51 AA M ASCVD 19 7.18
C3 45 C F Cardiac arrhythmia 16 6.69
C4 62 C M Cardiac arrest 19 6.48
C5 67 AA M ASCVD 17 6.68
C6 77 C M ASCVD 16 6.80
C7 33 AA M Drowning 21 7.20
Mean 55.80 18.00 6.84
SD 16.00 2.00 0.29
CONTROLS: MID-CAUDAL SAMPLES (N=6)
C8 28 C M Gunshot wound 7 6.82
C9 35 C M MVA 4 6.70
C10 41 AA F Cardiac disease 21 6.73
C11 48 C M Aneurysm 19 6.51
C12 72 C F MVA 17 6.83
C13 45 C F Pulmonary embolism 12 5.74
Mean 44.80 13.30 6.56
SD 15.10 6.83 0.42
A, atypical antipsychotic; AA, African American; APD, antipsychotic drug; ASCVD, arteriosclerotic cardiovascular disease; C, Caucasian; COD, cause of death; CUT,
chronic undifferentiated type; DVT, deep vein thrombosis; F, female; M, male; MI, myocardial infarction; NOS, not otherwise speciﬁed; MVA, motor vehicle accident;
PMI, postmortem interval; SD, standard deviation; SZ subtype, schizophrenia subtype; T, typical antipsychotic; TD, tardive dyskinesia; un, unknown; UNK, unknown
medication at time of death.
rat) using a mouse monoclonal anti-actin antibody (Millipore)
diluted 1: 40,000.
Antibodies speciﬁcity
In this work, we used two different types of antibodies to detect
TH, one type to detect total content of tyrosine hydroxylase, and
another type to detect the active (phosphorylated) form of this
enzyme. In addition, an antibody against actin was used as an
internal control for the accuracy of the experiments performed
(e.g., protein loading and tissue preservation control).
For the detection of total tyrosine hydroxylase, two different
antibodies were used: For the human studies, amousemonoclonal
anti-TH manufactured by Sigma-Aldrich (clone TH-16, catalog #
T2928) was used. As per information provided in the data sheet
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by the manufacturer, this antibody is raised against puriﬁed rat
tyrosine hydroxylase and recognizes an epitope in the N-terminal
region between amino acids 40 and 152 of human TH. For the rat
study, we used an anti-TH antibody manufactured by Millipore
(clone 2/40/15, catalog #MAB5280). As per information provided
by the manufacturer, this antibody is raised against puriﬁed tyro-
sine hydroxylase from a rat pheochromocytoma and its speciﬁcity
is routinely assessed by western-blot by the manufacturer.
For the detection of phosphorylated (active) tyrosine hydrox-
ylase, a rabbit polyclonal anti-phospho-ser40 antibody by Phos-
phosolutions (catalog # p1580-40) was used. As per information
provided by the manufacturer, this antibody is raised against a
phosphopeptide corresponding to amino acid residues surround-
ing the phosphor-ser40 of rat tyrosine hydroxylase. The antibody is
puriﬁed by afﬁnity puriﬁcation via sequential chromatography on
phospho and dephosphopeptide afﬁnity columns. The antibody
speciﬁcity was also tested by western-blot, and has been shown to
recognize exclusively pTH.
For the detection of actin, a mousemonoclonal anti-actin anti-
body byMillipore (catalog #MAB1501, clone C4) was used. As per
information provided by the manufacturer, this antibody is raised
against puriﬁed chicken gizzard actin, and recognizes an epitope
located at the N-terminal two-thirds of the protein near amino
acids 50–70. This antibody reacts against actin fromall vertebrates.
Protein extraction
Tissue collected for western-blot was diluted 1:5 in lysis buffer
containing Tris–HCl pH 8.0, sodium chloride, sodium dodecyl
sulfate, disodium EDTA, and a protease inhibitor cocktail (Sigma-
Aldrich; P8340). Samples were homogenized with a sonicator, and
the homogenate was centrifuged at 13,000 rpm for 15min at 4˚C.
The supernatant was recovered, and the total protein concentra-
tionwasmeasuredusing amodiﬁedLowry kit (Bio-Rad; 500-0113,
500-0114).
Gel electrophoresis and western-blot
Protein extracts with total protein concentrations of 30 (rat), or
60μg (human), were loaded onto 10% polyacrylamide gels along
with a molecular weight marker (Bio-Rad, Hercules, CA, USA;
161-0324). Proteins were resolved at 150V, and then transferred at
30V overnight onto PVDF membranes (Bio-Rad; 162-0174). The
following day, themembranes were blocked in Tris-buffered saline
(TBS) containing 5% non-fat powdered milk and 0.1% Tween-20
for 1 h at room temperature. THor pTHwere detected by incubat-
ing the membranes with the appropriate primary antibodies (see
above) diluted in TBS containing 1% non-fat powdered milk and
0.1% Tween-20 (TBSTm) for 21 h at 4˚C. After rinsing in TBSTm,
the membranes were incubated for 1 h at room temperature with
a goat anti-mouse alkaline phosphatase-coupled secondary anti-
body (Millipore; AP124A) diluted 1:15,000, or a goat anti-rabbit
alkaline phosphatase-coupled secondary antibody (Vector Lab-
oratories, Burlingame, CA, USA; AP-1000) diluted 1:1,000. The
membraneswere then rinsed inTBS, and the bandswere visualized
using a chemiluminescent system (Bio-Rad; 170-5018), exposing
KodakBioMaxXARﬁlms. In all cases, themembraneswere reblot-
ted and re-incubated with an antibody against actin (see details
above). Films were scanned at 600 dpi using a ﬂatbed scanner, and
optical density was measured using Image Pro-Plus 6.2 software
(Media Cybernetics).
STATISTICAL ANALYSIS
All data sets (outcome measures and possible covariates) were
assessed for normality using the Kolmogorov–Smirnov test. For
this and subsequent statistical tests, categorical variables (i.e., gen-
der and race) were assessed using a “dummy coding” scheme.
Power analyses were performed entering the outcome measures
(i.e., TH protein levels in schizophrenia and control groups) from
the ﬁrst postmortem study (pilot study) in G power 3.1 soft-
ware (Faul et al., 2007). For subsequent postmortem studies (i.e.,
regional expression of TH and pTH protein) an “a priori” test to
compute sample size for t -test comparison was used. For the ani-
mal study, an “a priori” test to compute sample size for one-way
ANOVAwas used. The effect of possible covariates in the outcome
measures of interest (i.e., mRNA TH levels, TH protein, and pTH
protein levels) for postmortem studies was assessed using a multi-
ple regression model, in which the effect of the possible covariates
was tested independently for each of the outcome measures of
interest. The covariates included in the multiple regression analy-
ses were carefully selected based on their possible inﬂuence on
the expression of TH (mRNA or protein) or pTH (protein). The
tested covariates included age, race, gender, postmortem interval
(PMI), pH, and actin levels. PMI and pH are directly related with
the quality of the tissue preservation (Stan et al., 2006), while actin
levels are directly relatedwith the accuracy on the processing of the
samples (i.e., loading of the samples on the electrophoresis gels).
The model of multiple regression analysis used also included the
assessment of possible multicollinearity. For the animal study, the
only covariate assessed was actin levels, and this was done by linear
regression analysis. For postmortem human studies the statistical
analysis of the outcome measures was performed by using the
appropriate t -test (i.e., Student’s t -test, or Welch’s t -test) for data
that were normally distributed, or a non-parametric test (Mann–
Whitney U -test), when one or both of the data sets were not
normally distributed. One-way ANOVA was used in the case of
animals treated with antipsychotics. The statistical analysis was
performed using InStat 3.0 software (GraphPad Software Inc., La
Jolla, CA, USA).
RESULTS
DEMOGRAPHIC FEATURES
Postmortem human cases were carefully selected for each study,
trying to match as much as possible the cases in the control and
schizophrenia groups by their age, gender, race, PMI, and brain pH
(see Tables 1 and 2). In addition, statistical analysis was performed
for each of these demographic features to ensure that the control
and schizophrenia groups were not signiﬁcantly different.
Pilot study
Age, gender, race, and PMI were not normally distributed
(Kolmogorov–Smirnov Normality test) for one or both groups,
therefore a Mann–Whitney U -test was used to compare each of
these demographic features between the control and schizophre-
nia groups (Age: U = 13.00; P = 0.79. Race: U = 11.00; P = 0.46.
Gender: U = 14.00; P = 0.91. PMI: U = 14.50; P > 0.99). Brain
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pH data were normally distributed for both groups, therefore a
standard unpaired t -test was performed [t (9) = 0.72; P = 0.49]. In
summary, all the demographic features were not signiﬁcantly dif-
ferent between the control and schizophrenia groups for the pilot
study (Table 1).
Regional expression of TH and pTH study
This study was performed in two different types of samples that
were analyzed independently: Cases containing all the rostro-
caudal extent of the SN/VTA, and cases containing only the
mid-caudal region of the SN/VTA. The demographic features
for control and schizophrenia cases for each of these two types
of samples were statistically analyzed. In rostro-caudal samples,
age, PMI, and brain pH were normally distributed for the control
and schizophrenia groups, therefore an unpaired t -test was per-
formed [Age: t (12) = 0.15; P = 0.89. PMI: t (12) = 0.40; P = 0.70.
Brain pH: t (12) = 1.79; P = 0.1]. On the other hand, race and gen-
der for the rostro-caudal samples were not normally distributed
at least for one of the groups, therefore a Mann–Whitney U -test
was performed (Race: U = 18.00; P = 0.39. Gender: U = 22.00;
P = 0.79). In summary, no demographic features were signiﬁ-
cantly different between the control and schizophrenia groups for
the cases containing all the rostro-caudal extent of the SN/VTA.
In mid-caudal samples, age, PMI, and pH were normally dis-
tributed for the control and schizophrenia groups, therefore an
unpaired t -test was performed [Age: t (12) = 1.08; P = 0.30. PMI:
t (12) = 0.50; P = 0.63; Brain pH: t (12) = 1.70; P = 0.11]. For mid-
caudal samples race and gender were not normally distributed
and a Mann–Whitney U -test was performed (Race: U = 10.00;
P = 0.045. Gender: U = 18.00; P = 0.39). In summary, race was
the only demographic feature that presented signiﬁcant differences
between the schizophrenia and control groups inmid-caudal sam-
ples. This signiﬁcant difference was further assessed (see below,
second postmortem study results) as a possible predictor for the
main outcome measures (TH and pTH protein levels; Table 2).
PILOT STUDY: TH mRNA AND PROTEIN EXPRESSION IN HUMAN
POSTMORTEM SCHIZOPHRENIA AND CONTROL CASES
TH mRNA and TH protein levels were tested in SN/VTA samples
from the same cases (see Table 1). In this pilot study a total of 11
cases were used (n = 5 controls; n = 6 schizophrenia).
TH mRNA levels
Multiple regression analysis with the main outcome measure (TH
mRNA levels) as the dependent variable, and the possible covari-
ates as independent variables was used to test if the covariates
(i.e., age, race, gender, PMI, pH) signiﬁcantly affected the TH
mRNA levels regardless of diagnoses (schizophrenia or control).
The results of this test were non-signiﬁcant (R2 = 0.38; P = 0.70).
After that, TH mRNA data in the schizophrenia and control
groups were tested for normality using the Kolmogorov–Smirnov
test. For both groups the TH mRNA data were normally distrib-
uted (Control group: KS= 0.23; P > 0.10. Schizophrenia group:
KS= 0.23; P > 0.10). Since the data were normally distributed,
an unpaired two-tailed t -test assuming equal variances was per-
formed to test for differences in THmRNA levels between the con-
trols and schizophrenia groups, which yielded a non-signiﬁcant
result [t (9) = 1.74; P = 0.12]. See also Figure 1A.
TH protein levels
Multiple regression analysis with TH protein as the main out-
come measure (dependent variable) and age, race, gender, PMI,
pH, and actin levels as possible covariates (independent vari-
ables) revealed a non-signiﬁcant result (R2 = 0.60; P = 0.52).
Kolmogorov–Smirnov normality test revealed that TH protein
levels data in the control and schizophrenia groups were nor-
mally distributed (Control group: KS= 0.21; P > 0.10. Schizo-
phrenia group: KS= 0.29; P > 0.10). An unpaired two-tailed t -
test assuming unequal variances (Welch’s correction) was used
since the SDs between the two groups were signiﬁcantly differ-
ent (F = 72.75; P = 0.001). The t -test with Welch’s correction
revealed signiﬁcant differences in TH protein levels between the
control and schizophrenia groups [t (5) = 2.96;P = 0.031]. See also
Figure 1B.
In summary, this pilot study showed that TH protein levels
were signiﬁcantly different between the schizophrenia and con-
trol groups, while TH mRNA levels did not differ between the
two groups. These results prompted us to design new experiments
to test: (a) if chronic antipsychotic treatment could signiﬁcantly
affect the levels of TH protein (animal study), and (b) if the differ-
ences observed in TH protein expression were regionally speciﬁc
within the SN/VTA, and if these differences were also present in
the active form of TH (pTH), which were tested in a subsequent
postmortem human study.
ANIMAL STUDY: ANTIPSYCHOTIC TREATMENT EFFECT ON TH PROTEIN
LEVELS
Power analysis
For this study, an“a priori”power analysis was performed to deter-
mine the minimum adequate sample size for a one-way ANOVA
with a minimum power of 0.80. Taking into account the results of
the pilot study for TH protein levels in postmortem human tissue,
we used the following assumption: if changes in TH protein levels
can be explained as an effect of the antipsychoticmedication, these
changes have to be large to explain the differences observed in the
pilot study between the control and schizophrenia groups. For this
reason, we modeled the study to expect a large effect size (0.80).
With these assumptions, the power analysis determined that amin-
imum sample size of n = 21 (n = 7 per group) was necessary to
obtain the minimum power required. Since in our study the sam-
ple size was n = 27 animals (n = 9 per group), a post hoc power
analysis using the actual effect size obtained (f = 0.64) revealed
that the actual power of our study was 0.804 (critical F = 3.40;
α= 0.05).
TH protein levels in animals chronically treated with APDs
The only covariate to be assessed for this study was actin protein
levels, which is a measurement of the accuracy of the experi-
ment. The effect of this possible covariate on TH protein lev-
els was analyzed by linear regression, which revealed a non-
signiﬁcant result (r = 0.15; P = 0.44). The Kolmogorov–Smirnov
test showed that TH protein levels were normally distributed for
the three groups (Control group: KS= 0.22; P > 0.10; Haloperi-
dol group: KS= 0.17; P > 0.10. Olanzapine group: KS= 0.26;
P = 0.08). However, a Kruskal–Wallis non-parametric ANOVA
was used, since a Bartlett’s test for homogeneity of variances
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FIGURE 1 | Pilot study:TH mRNA and protein levels in schizophrenia
and control cases. *P< 0.05. (A)TH mRNA levels in control (n= 5) and
schizophrenia (n= 6) cases. The top panel shows representative images of
TH mRNA in situ hybridization in rostral (R), medial (M), and caudal (C)
sections of the SN/VTA of a control case (C2), and a schizophrenia case
(SZ2). Comparison of the mean values for TH mRNA OD is shown in the
bar graph (middle panel). Mean optical density (OD) values for TH mRNA
levels in control and schizophrenia (SZ) cases did not differ signiﬁcantly
(P = 0.12; OD mean±SD: control= 0.187± 0.027,
schizophrenia= 0.161± 0.023). The bottom panel shows a scatter plot for
the individual TH mRNA OD values. The horizontal bar in the scatter plot
indicates the mean OD value for each group. Note the dense clustering of
all the OD values for both groups. (B)TH protein levels in the same control
and schizophrenia cases used for the mRNA study. The top panel shows
representative images of the same western-blot membrane, ﬁrst blotted
for TH protein, and then reblotted for actin. This membrane contained all
the control (C1–C5) and schizophrenia (SZ1–SZ6) cases used in this pilot
study. Note the conspicuous difference in blot signal among the different
samples in theTH western-blot image, while actin expression is uniform
among all cases. The comparison of the means for TH protein levels in
controls and schizophrenia is shown in the mid panel (bar graph). OD
values for TH protein were signiﬁcantly different (*) between the two
groups (P = 0.031; OD mean±SD: control= 0.912± 0.046,
schizophrenia= 0.433± 0.393). The bottom panel shows a scatter plot for
the individual TH protein OD values. The horizontal bar in the scatter plot
indicates the mean OD value for each group. Note the dense clustering of
the OD values for the control group, while in the schizophrenia group there
is a large scattering of the data. However, note that in the lower TH
expression cluster, two cases presented the same exact TH OD value and
are represented in the scatter plot as a single circle.
showed very signiﬁcant differences among the three groups
(Bartlett statistic= 10.37;P = 0.006). TheKruskal–WallisANOVA
revealed non-signiﬁcant differences among the three groups for
TH protein levels (KW= 1.79; P = 0.41). See also Figure 2.
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FIGURE 2 | Animal study: antipsychotic treatment effect onTH protein
levels. (A)Western-blot images of TH protein for all the animals of the three
treatment groups. All the samples (n= 9 per treatment group) were incubated
and developed together on the same ﬁlm to accurately measure OD. Note the
homogeneity of expression of TH for all cases independently of the treatment
group. (B)The same western-blot membrane shown in A was reblotted for
the detection of actin protein. (C) Comparison of the mean OD for TH protein
levels showed no signiﬁcant differences among the three groups (P = 0.41;
OD mean±SD: control= 0.824± 0.181, haloperidol= 0.917± 0.049,
olanzapine= 0.973± 0.136). (D) Scatter plot graph showing the individual TH
protein OD values for the three groups. The horizontal bar in the scatter plot
indicates the mean OD value for each group.
In summary, this study showed that chronic treatment with
antipsychotic medications (typical or atypical) did not produce
signiﬁcant differences in TH protein levels when compared with
untreated controls.
SECOND POSTMORTEM STUDY: REGIONAL EXPRESSION OF TH AND
PHOSPHORYLATED TH
Power analysis
For this study, an“a priori”power analysis was performed to deter-
mine the minimum adequate sample size for a two-tailed t -test
analysis with a minimum power of 0.80. To calculate this, data
obtained from the THprotein levels in the pilot studywere entered
to calculate the effect size. This analysis yielded that a sample size of
n = 14 cases (schizophrenia n = 8; control n = 6) would produce
an actual power of 0.83 (t critical= 2.18; α= 0.05). Inmid-caudal
samples, an outlier was present in the schizophrenia group (case
SZ11). This case was detected as an outlier using a combination
of different factors: ﬁrst, the pH of this sample was highly basic
(pH= 7.80, see Table 2); second, TH levels were highly different
from any other case in the schizophrenia or control groups, and a
Grubb’s test was performed using Quick Calcs Online calculator
(GraphPad Software Inc.). This test showed that case SZ11 was a
signiﬁcant outlier for TH levels (Z = 2.94;P < 0.05). For these rea-
sons, this casewas removed from the subsequent statistical analysis
of mid-caudal TH and pTH expression. After removing this case
for the analysis, a two-tailed t -test“compromise”power was calcu-
lated, entering the data obtained for TH protein levels in the pilot
study to calculate the effect size. This analysis yielded a power of
0.80 (critical t = 2.20; α= 0.05) for the mid-caudal analysis with
a sample size of n = 13 (control n = 6; schizophrenia n = 7).
TH protein levels in rostro-caudal SN/VTA samples
Multiple regression analysis with TH protein as the main outcome
measure (dependent variable) and age, race, gender, PMI, pH, and
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actin levels as possible covariates (independent variables) revealed
a non-signiﬁcant result (R2 = 0.74; P = 0.06). Kolmogorov–
Smirnov normality test revealed that TH protein levels in the con-
trol and schizophrenia groups were normally distributed (Con-
trol group: KS= 0.31; P = 0.07. Schizophrenia group: KS= 0.17;
P > 0.10). An unpaired two-tailed t -test assuming unequal vari-
ances (Welch’s correction) was used since the SDs between the
two groupswere signiﬁcantly different (F = 32.97;P = 0.001). The
t -test with Welch’s correction revealed signiﬁcant differences in
TH protein levels between the control and schizophrenia groups
[t (7) = 2.59; P = 0.036]. See also Figure 3A.
TH protein levels in mid-caudal SN/VTA samples
Multiple regression analysis with TH protein as the main outcome
measure and age, race, gender, PMI,pH, and actin levels as possible
covariates revealed a non-signiﬁcant result (R2 = 0.75; P = 0.11).
In addition, the multiple regression analysis showed that, even
when race was detected as a signiﬁcantly different demographic
feature between the schizophrenia and control groups for mid-
caudal cases (see demographic features analysis above), this was
not a signiﬁcant contributor (predictor) of TH levels outcome
(t ratio= 0.75; P = 0.48). Kolmogorov–Smirnov Normality test
revealed that TH protein levels were normally distributed for the
control group but not for the schizophrenia group (Control group:
KS= 0.27; P > 0.1. Schizophrenia group: KS= 0.31; P = 0.047).
Since data were not normally distributed for one of the groups,
a non-parametric Mann–Whitney U -test was used. This test
revealed non-signiﬁcant differences in TH protein levels between
the control and schizophrenia groups (U = 13.0; P = 0.29). See
also Figure 3A.
Phosphorylated TH protein levels in rostro-caudal SN/VTA samples
Multiple regression analysis with pTH protein levels as the main
outcome measure, and age, race, gender, PMI, pH, and actin levels
as possible covariates revealed a non-signiﬁcant result (R2 = 0.51;
P = 0.39). Kolmogorov–Smirnov normality test revealed that pTH
protein levels data in the control and schizophrenia groups were
normally distributed (Control group: KS= 0.27; P > 0.10. Schiz-
ophrenia group: KS= 0.27; P = 0.09). An unpaired two-tailed t -
test assuming unequal variances yielded no signiﬁcant differences
[t (12) = 2.12; P = 0.056], although the P value was low enough to
indicate a trend toward signiﬁcance. See also Figure 3B.
Phosphorylated TH protein levels in mid-caudal SN/VTA samples
Multiple regression analysis with pTH protein as the main out-
come measure and age, race, gender, PMI, pH, and actin levels
as possible covariates revealed a non-signiﬁcant result (R2 = 0.73;
P = 0.13). In addition, the multiple regression analysis showed
that, evenwhen racewas detected as a signiﬁcantly different demo-
graphic feature between the schizophrenia and control groups for
mid-caudal cases (see demographic features analysis above), this
was not a signiﬁcant contributor (predictor) of pTH levels out-
come (t ratio= 0.36; P = 0.73). Kolmogorov–Smirnov normality
test revealed that pTH protein levels were normally distributed
for the control group but not for the schizophrenia group (Con-
trol group: KS= 0.24; P > 0.1. Schizophrenia group: KS= 0.35;
P = 0.01). Since data were not normally distributed for one of
the groups, a non-parametric Mann–Whitney U -test was used.
This test revealed non-signiﬁcant differences in TH protein lev-
els between the control and schizophrenia groups (U = 12.5;
P = 0.25). See also Figure 3B.
In summary, this regional postmortem study showed that TH
protein levels in samples containing the entire rostro-caudal extent
of the SN/VTA were signiﬁcantly different between the schizo-
phrenia and control groups, while no signiﬁcant differences were
detected in samples that only contained mid-caudal regions. In
addition, no signiﬁcant differences were detected for pTH protein
levels for samples containing either the entire rostro-caudal, or
only mid-caudal regions of the SN/VTA. However, a trend toward
signiﬁcance (P = 0.056) was observed for pTH levels in samples
containing the entire rostro-caudal extent of the SN/VTA.
DISCUSSION
As far as we are aware, this is the ﬁrst study to analyze TH pro-
tein levels in the SN/VTA of schizophrenia compared to controls,
and only two previous studies have assessed TH mRNA levels in
schizophrenia (Ichinose et al., 1994; Mueller et al., 2004).
PILOT STUDY: TH mRNA AND PROTEIN EXPRESSION IN HUMAN
POSTMORTEM SCHIZOPHRENIA AND CONTROL CASES
The most remarkable ﬁnding of our ﬁrst postmortem study (pilot
study) was the fact that in some of the schizophrenia cases (three
out of the six cases studied) TH protein levels were profoundly
altered, while in the same brain samples TH mRNA levels were
similar to control cases. It was also remarkable the large variability
presented in the schizophrenia group, with some cases present-
ing levels in the same range than controls, while others presented
very low TH protein levels. The regulation of the transcription
and translation of the TH gene is a highly complex process that is
also speciﬁc to the type of TH expressing cell (i.e., dopaminergic
versus adrenergic or noradrenergic neurons). Tank and collab-
orators have shown that while in adrenergic and noradrenergic
cell populations of the locus coeruleus and adrenal medulla TH
is highly regulated at the transcription level, this type of regula-
tion is minimal in the case of dopaminergic cells of the SN/VTA
(Chen et al., 2008; Tank et al., 2008). In the locus coeruleus and
adrenal medulla, most types of stress can induce short-term and
long-term upregulation of TH mRNA transcription, that is well
correlated with upregulation of TH protein levels (Alterio et al.,
2001; Wong and Tank, 2007; Tank et al., 2008). This is also cor-
related with changes in transcription factors that are known to
regulate the TH gene promoter (Wong and Tank, 2007; Tank et al.,
2008). However, in the case of the TH expressing cells of the
SN/VTA it has been shown that induction of the transcription
for TH mRNA does not always lead to an upregulation of TH
protein levels (Chen et al., 2008; Tank et al., 2008). The applica-
tion of drugs that are known to affect the transcription rate of
TH mRNA in the adrenal medulla and the locus coeruleus (Alte-
rio et al., 2001; Wong and Tank, 2007; Tank et al., 2008), does
not produce any effect in TH mRNA levels in the SN/VTA, while
they produce an upregulation of TH protein levels (Chen et al.,
2008; Tank et al., 2008). In midbrain slice explants containing the
SN/VTA, these authors demonstrated that forskolin and cAMP
analogs increase TH protein levels in a dose-dependent manner,
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FIGURE 3 | Second postmortem study: regional distribution ofTH and
pTH. *P < 0.05; #P > 0.05< 0.06. (A)The top panel shows images of two
western-blots for TH that were developed on the same ﬁlm, containing all the
cases used in this study. Note that rostro-caudal and mid-caudal cases were
run together in the same gels. In addition, reblots for actin of the same
membranes are shown immediately below. The graph bar (mid panel) shows
the comparison of the mean OD values for TH protein in rostro-caudal and
mid-caudal samples for controls and schizophrenia. Only the rostro-caudal
samples showed signiﬁcant differences (*) between schizophrenia and
control cases (P = 0.036; OD mean±SD: control
rostro-caudal= 0.749± 0.044, schizophrenia rostro-caudal= 0.513± 0.252;
control mid-caudal= 0.743± 0.107, schizophrenia mid-caudal= 0.712± 0.261).
The bottom panel shows a scatter plot for the individual TH OD data. The
horizontal bar in the scatter plot indicates the mean OD value for each group.
(B)The same membranes in (A) were reblotted for the detection of pTH (top
panel). In addition, reblots for actin of the same membranes are shown
immediately below. The graph bar in the mid panel shows the comparison of
the mean OD values for pTH in rostro-caudal and mid-caudal samples. Even
when there were no signiﬁcant differences in pTH OD values between
controls and schizophrenia in rostro-caudal samples, a trend (#) toward
signiﬁcance was observed (P = 0.056; OD mean±SD: control
rostro-caudal= 0.405± 0.120, schizophrenia rostro-caudal= 0.203± 0.208;
control mid-caudal= 0.421± 0.168, schizophrenia
mid-caudal= 0.419± 0.246). For comparison, the dashed line on top of each
of the individual bars indicates the mean level of total TH for each group. The
ratio of pTH versus total TH for each group was as follows: control
rostro-caudal= 54.07%, schizophrenia rostro-caudal= 39.57%; control
mid-caudal= 56.66%, schizophrenia mid-caudal= 58.85%.The bottom panel
shows a scatter plot for the individual pTH OD data. The horizontal bar in the
scatter plot indicates the mean OD value for each group.
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while TH mRNA levels are unchanged. These authors proposed
that in the midbrain there is a cAMP-mediated induction of TH
protein by a translational mechanism that includes the formation
of binding complexes with Poly(C)-binding proteins, producing
the stabilization of TH mRNA, and/or increase of its association
withpolysomes,ﬁnally leading to increased translation (Tank et al.,
2008).
The only two previous studies addressing TH mRNA levels
in schizophrenia reported opposite results. One of these studies
(Ichinose et al., 1994) showed that, as in our study, TH mRNA
levels in schizophrenia were unchanged compared to controls.
A second study (Mueller et al., 2004) showed signiﬁcantly ele-
vated levels of TH mRNA in schizophrenia. Several factors can
contribute to this difference in the results obtained, including
differences in the cohort of patients as well as methodological
differences.
ANIMAL STUDY: ANTIPSYCHOTIC TREATMENT EFFECT ON TH PROTEIN
LEVELS
In our study, we also addressed the possibility that the observed
changes in TH protein in the SN/VTA of schizophrenia patients
could be an effect of antipsychotic drug treatments. Our results
showed that chronic treatment with antipsychotic medication did
not produce signiﬁcant changes in TH protein expression in the
SN/VTA of rodents. Supporting our ﬁndings, a previous study
in rodents using a different atypical antipsychotic (clozapine) has
shown similar results for the SN/VTA dopaminergic cells, with no
changes in THprotein levels or TH immunolabeling (Tejedor-Real
et al., 2003). In addition, it has been shown that chronic treatment
with haloperidol does not produce changes in TH axonal density
in the prefrontal and entorhinal cortex of monkeys, while lamina-
speciﬁc changes in TH axonal density are present in schizophrenia
patients on antipsychotic medication (Akil et al., 1999, 2000).
Two laboratories have reported changes in cell morphology and
TH immunolabeling in the SN/VTA after chronic treatment with
haloperidol (Levinson et al., 1998; Mazurek et al., 1998; Marchese
et al., 2002). However, in these studies drugs were administered
in very high doses. Mazurek and collaborators performed two
studies using intraperitoneal injections of haloperidol once a day
in doses ranging from 1 to 10mg/kg/day (Levinson et al., 1998;
Mazurek et al., 1998). The other group found changes in animals
that were subcutaneously administered haloperidol twice a day at
a dose of 1mg/kg (Marchese et al., 2002). The doses used by these
investigators are between 10- and 100-fold the dose necessary to
achieve receptor occupancies equivalent to therapeutic conditions
(Kapur et al., 2003), which can lead to cellular toxicity. Finally,
another chronic rodent study using haloperidol or combinations
of haloperidol and quetiapine did not ﬁnd any morphological
anomalies in the dopaminergic neurons of the SN/VTA (Zhang
et al., 2007).
SECOND POSTMORTEM STUDY: REGIONAL EXPRESSION OF TH AND
PHOSPHORYLATED TH
Our second postmortem study addressed the regional expression
of TH and pTH protein using two different types of samples:
One set of cases contained the entire rostro-caudal extent of the
SN/VTA, and another set contained only mid-caudal regions.
Compared to controls, schizophrenia rostro-caudal samples
presented signiﬁcant differences in TH protein levels, while for
pTH there was a trend toward signiﬁcance. However, in the case
of samples containing only mid-caudal regions there were no dif-
ferences detected between schizophrenia and controls for TH or
pTH protein levels. These results are especially interesting because
there is a regional segregation on the projections from the SN/VTA
complex to cortical and subcortical regions. The rostral to mid-
regions of the SN/VTA complex contain the rostral part of the
dorsal tier of the SNc and the adjacent VTA. Both of these neu-
ronal groups project preferentially to the prefrontal, entorhinal,
and piriform cortex, as well to the ventral striatum and the amyg-
dala (Fallon and Moore, 1978a,b; Fallon et al., 1978a,b; Porrino
and Goldman-Rakic, 1982; Gaspar et al., 1992; McRitchie et al.,
1995; Haber and Fudge, 1997; Halliday, 2004). The mid to caudal
regions of the SN/VTA complex contain the remainder of the dor-
sal tier, as well as the entire ventral tier of the SNc that projects
preferentially to the dorsal striatum (Fallon and Moore, 1978a,b;
Fallon et al., 1978b;McRitchie et al., 1995; Haber and Fudge, 1997;
Joel and Weiner, 2000; Halliday, 2004). Our ﬁndings indicate that
the tyrosine hydroxylase anomalies are located preferentially (or
exclusively) in the rostral areas of the SN/VTA complex. This ﬁnd-
ing suggests that TH protein anomalies could be preferentially
located in the mesocortical and mesolimbic pathways. Support-
ing this, anomalies in TH immunolabeling have been found in
speciﬁc layers of the prefrontal and entorhinal cortex in schiz-
ophrenia (Akil et al., 1999, 2000; Lewis and Gonzalez-Burgos,
2006).
Although TH protein levels have not been assessed before, a
previous study in a cohort of Japanese patients addressed TH
enzymatic activity in the SN/VTA of schizophrenia compared
to controls (Toru et al., 1988). TH enzymatic activity is linked
with the portion of the TH protein that is active, which in our
study we assessed by measuring the levels of pTH. In brain tis-
sue, it has been shown that TH can be phosphorylated at several
serine residues, including serine 19, 31, and 40, all located in
the ﬁrst 40 amino acids of the N-terminus (Haycock, 1990).
Among these serine phosphorylation sites, serine 40 appears to
be the most relevant for the activation of TH (Haycock, 1990;
Nakashima et al., 2009), and the positively charged amino acids
ﬂanking this serine play an important role in the proper phos-
phorylation of this site (Nakashima et al., 2009). This serine
phosphorylation area is considered a modulatory region for the
activity of the catalytic subunit of the TH protein, since phos-
phorylation in this area produces an enhancement of the activity
of TH (Haycock, 1990; Nakashima et al., 2009). Our study of
pTH levels in schizophrenia showed a trend toward a signiﬁcant
difference compared to controls in the samples containing the
entire rostro-caudal extent of the SN/VTA, while no differences
where observed for the samples containing mid-caudal regions.
Toru et al. (1988) in their work assessing TH enzymatic activ-
ity reported a signiﬁcant increase in TH activity in the SN/VTA
of schizophrenia samples. In our study, pTH levels presented a
very heterogeneous proﬁle: For the samples containing the entire
rostro-caudal extent of the SN/VTA, pTH levels were lower or
equal than in control samples, while for the cases containing only
mid-caudal regions, pTH levels ranged from higher than controls
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to lower (see scatter plot graphs in Figure 3B). The discrepancy
between our results and the previous study by Toru et al. (1988)
may be due to several factors. This includes differences in the
area selected for study (e.g., their dissection included only the
substantia nigra, while we included in our study the substan-
tia nigra and the VTA as a dopaminergic producing complex),
differences in the cohort of patients, and the use of different
techniques.
Another interesting ﬁnding was that TH protein levels were
very variable in schizophrenia, while were rather constant in the
control group, which suggests that the schizophrenia group has a
large heterogeneity of TH expression anomalies. Based on previ-
ous studies concerning the regulation of TH expression, genetic
studies of the TH gene in schizophrenia, and in our data, we
hypothesize that different anomalies in the TH gene and mod-
ulatory elements in the translation of the protein may account for
this heterogeneity. A large number of genetic association studies
for the TH gene have found very diverse results. The most con-
sistent association was found for intron 1 of the TH gene (TH01
locus), an area that has been postulated as a modulatory element
for TH transcription (Pae et al., 2003; Jacewicz et al., 2008). In
the TH01 locus, certain alleles of a DNA microsatellite sequence
repeat have been linked with a signiﬁcant higher risk for schizo-
phrenia. However, this association was found in some cohorts of
patients (Meloni et al., 1995;Wei et al., 1995; Kurumaji et al., 2001;
Pae et al., 2003; Jacewicz et al., 2008, but not in others; Burgert
et al., 1998; Jonsson et al., 1998). In addition, TH protein synthe-
sis is a highly regulated process, with epigenetic, transcriptional,
and posttranscriptional regulations (Lenartowski and Goc, 2011)
that vary depending on the class of catecholaminergic neuron
(i.e., dopaminergic versus adrenergic or noradrenergic; Tank et al.,
2008). Our data strongly support that TH anomalies in schizo-
phrenia occur at the posttranscriptional level, which may include
anomalies in the stabilization of themRNA, the proper attachment
of mRNA to polysomes, and/or the efﬁcacy of translation of the
mRNA into protein.
CONCLUSION
In summary, our study shows for the ﬁrst time that an anomaly
in TH protein synthesis is present in the SN/VTA in schizophre-
nia. Since this pathology is present in the protein, but not in the
mRNA, it strongly suggests that the anomalies occur during post-
transcriptional processes,but thiswill require further investigation
to identify the exact processes that are affected. Finally, our study
provides the ﬁrst data indicating that within the SN/VTA, the
anomalies in the synthesis of TH may be restricted to speciﬁc
dopaminergic neuronal populations, mostly located in the rostral
regions of this complex. This suggests that anomalies in TH syn-
thesis may be linked with pathologies in the mesocortical and/or
mesolimbic dopamine pathways,but further studieswill be needed
to pinpoint the speciﬁc populations affected.
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